Tirzepatide

Tirzepatide is a synthetic 39-residue peptide incorporating non-proteinogenic residues and a C20 fatty diacid moiety attached via a linker, a modification that promotes albumin binding and extends circulating half-life. It is supplied as a lyophilised solid. A peptide of this length with a lipid modification places real demands on analytical verification: reversed-phase HPLC purity against a stated gradient, mass-spectrometric identity confirmation, and peptide content determination are all relevant, and lipidated peptides behave differently on standard methods. Values on this record are transcribed from supplier documentation.

Tirzepatide was developed as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, following two decades of incretin pharmacology that began with the characterisation of GLP-1 and the development of single-receptor agonists. It completed a large randomised clinical programme and holds marketing authorisation as a prescription medicine in multiple jurisdictions. That authorisation applies to a licensed pharmaceutical product supplied under medical supervision, and to nothing on this page.

Published work examines receptor binding and signalling bias at the GIP and GLP-1 receptors, effects on glucose-dependent insulin secretion, glucagon suppression, gastric emptying, appetite regulation via central pathways, and downstream effects on glycaemic and body-weight endpoints measured in trial populations. Pharmacokinetics of the lipidated molecule, including albumin binding and half-life supporting weekly dosing intervals in the clinical product, are characterised in published studies.

Signalling bias at the GIP and GLP-1 receptors has itself been a subject of published mechanistic work, including studies examining the relative potency at each receptor and the degree of beta-arrestin recruitment versus G-protein coupling. The physiological contribution of the GIP component remains an active question in the literature, since GIP receptor agonism and antagonism have both been reported to produce weight effects in experimental systems, and that unresolved tension is a reasonable thing for a reader to know.

The clinical evidence base is large by any standard: multiple randomised, double-blind, active- and placebo-controlled trials enrolling thousands of participants, with pre-registered endpoints, independent adjudication and long follow-up. Glycaemic and body-weight effects were statistically robust and replicated across separate trials and populations. Pharmacokinetics, immunogenicity and adverse-event profiles were characterised to regulatory standard. Cardiovascular and other outcome data have been published from dedicated trials.

The programme also reported comparative data against an active incretin comparator rather than placebo alone, which is a more demanding design and materially stronger evidence than placebo superiority. Discontinuation rates, adverse-event frequencies by dose, and the distribution rather than only the mean of weight and glycaemic responses were published. Independent analyses and meta-analyses have since been conducted by groups with no role in the original trials, which is the kind of external scrutiny absent from nearly every other record in this catalogue.

The strength of that evidence attaches to a licensed product manufactured under pharmaceutical quality systems, and it does not transfer to research-grade material. No published data establish equivalence between research-grade peptide and the licensed product in identity, related-substance profile, aggregation state, sterility or endotoxin content. Gastrointestinal adverse events were common in the trials and are frequently understated in secondary summaries. Durability after discontinuation is limited, with weight regain reported in withdrawal studies. Long-term data beyond the published trial windows remain limited, and populations excluded from the trials were not characterised. This record exists for analytical reference only.

Store the lyophilised solid per the storage conditions on this record, protected from light and moisture, equilibrating the sealed vial to ambient temperature before opening. Lipidated peptides of this length are prone to aggregation, and agitation, repeated freeze-thaw and prolonged solution storage are the handling variables most often implicated in analytical failure. This section describes laboratory handling of the material as supplied; it contains no preparation, reconstitution-to-dose or administration procedure.

Indexed citations with verified PMIDs appear below and link to the primary records. See testing methodology for the analytical basis of these values and sourcing standards for the documentation expected with each batch.